Biology subjects

Ellrott, K.

Publications and source records attributed to Ellrott, K..

14 recordsLinked to original sources

bioRxiv2026

The GA4GH Workflow Execution Service: A Standard API for Workflow Execution and Management in Genomics

Rapid growth in life science data generation has led to large and increasingly distributed collections of sensitive genomic data. To analyse this data, researchers increasingly rely on computational workflows to enable scalable, portable and reproducible analysis. However, these workflows are executed by specialized workflow engines across heterogeneous compute environments, each with its own requirements. As a result, users often need engine- and compute-environment-specific knowledge to submit, monitor and manage workflow execution, increasing the barriers to interoperability. These challenges are compounded in large-scale projects, where workflow runs must be dispatched to local clusters, cloud platforms or data hosting infrastructures with different underlying technologies. We describe the Global Alliance for Genomics and Health (GA4GH) Workflow Execution Service (WES) API, an approved GA4GH standard first released in 2018, together with its data model and the endpoints that define a unified interface for workflow execution. By standardizing workflow invocation, the WES API allows a single client to submit, monitor and cancel workflow runs across diverse workflow engines and compute backends, such as scheduling clusters or cloud platforms. We surveyed thirteen adoptions of the standard, covering standalone services and platforms in four programming languages. In a two-site demonstration, a WES implementation from Germany and one from Japan executed the same federated allele-frequency analysis with site-specific adjustments and only aggregated results leaving either site, demonstrating that it is possible to run the same analysis across independently built and operated WES services in different countries. From the gaps identified, we propose extensions for community discussion.

bioinformatics↗

bioRxiv2025

FHIR as a Unifying Format for Genomic Research Data Tracking, Aggregation, and Integration

The increasing complexity of genomic research demands standardized data sharing and integration. The Fast Healthcare Interoperability Resources (FHIR) specification has become a well-established standard for exchanging data among health data systems. While designed primarily for clinical and patient data in health care environments, it also has applicability to represent genomic research data and offers a path for aggregating and integrating extremely rich datasets that have traditionally remained siloed and disparate. To study this potential, we developed FHIR Aggregator, an integration of seven major biomedical repositories, including the Genomic Data Commons, GTEx, HTAN, and DepMap, that covered 142334 patients, 819251 specimens, 1096491 observations and 711166 documents. We explore the various ways the FHIR standard can be applied to structure genomic research data and enable new possibilities. We demonstrate how FHIR can be used, where it succeeds or falls short, and which concepts must be extended to better support large-scale clinical and genomics research projects.

bioinformatics↗

bioRxiv2025

Robust software development practices improve citations of RNA-seq tools

RNA sequencing (RNA-seq) has emerged as an exemplary technology in biology and clinical applications, offering a crucial complement to other transcriptomic profiling protocols due to its high sensitivity, precision, and accuracy in characterizing transcriptomes. However, the rapid proliferation of RNA-seq tools necessitates the adoption of robust software development practices. Such development underscores the critical need to examine how RNA-seq tools are developed, maintained, and distributed; and whether the data they generate is reproducible as all of these factors are essential for ensuring software reliability, transparency, and trust in scientific findings. We conducted a comprehensive assessment of 434 RNA-seq tools developed between 2008 and 2024, categorizing them based on the type of analysis they perform. Our evaluation encompassed their software development and distribution methodologies, as well as the attributes contributing to their widespread adoption and dependability within the biomedical community, which were quantified by factors such as package manager availability, containerization, multithreading support, documentation quality, and inclusion of example datasets. Our findings establish the first documented positive association between rigorous software development practices and their adoption of published RNA-seq tools as measured by citations (Mann-Whitney U test, p-value = 4.9 x 10-26). By identifying key characteristics of widely adopted software, our findings guide developing robust and user-friendly RNA-seq tools, thereby reinforcing the call for rigorous community-wide standards.

bioinformatics↗

bioRxiv2025

Aggregating multimodal cancer data across unaligned embedding spaces maintains tumor of origin signal

AI based embeddings offer the possibilities of encoding complex biological data into low dimensional spaces, called embedding spaces, that maintain the relationships between entities. There is an open question about the compatibility of embedding spaces that are created without any coordination. It has been assumed that signals in these unaligned embedding spaces would be destroyed if vectors were aggregated into summed values. We trained embedding models across different data modalities and tested aggregating the values together to test this assumption. Our research shows that signal from unaligned embedded values is conserved and able to still be used for learning tasks, such as data modality and tumor of origin recognition.

bioinformatics↗

bioRxiv2022

recountmethylation enables flexible analysis ofpublic blood DNA methylation array data

Thousands of DNA methylation (DNAm) array samples from human blood are publicly available on the Gene Expression Omnibus (GEO), but they remain underutilized for experiment planning, replication, and cross-study and cross-platform analyses. To facilitate these tasks, we augmented our recountmethylation R/Bioconductor package with 12,537 uniformly processed EPIC and HM450K blood samples on GEO as well as several new features. We subsequently used our updated package in several illustrative analyses, finding (1) study ID bias adjustment increased variation explained by biological and demographic variables, (2) most variation in autosomal DNAm was explained by genetic ancestry and CD4+ T-cell fractions, and (3) the dependence of power to detect differential methylation on sample size was similar for each of peripheral blood mononuclear cells (PBMC), whole blood, and umbilical cord blood. Finally, we used PBMC and whole blood to perform independent validations, and we recovered 40-46% of differentially methylated probes (DMPs) between sexes from two previously published epigenome-wide association studies (EWAS).

bioinformatics↗

bioRxiv2021

Inverting the model of genomics data sharing with the NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL)

The traditional model of genomic data analysis - downloading data from centralized warehouses for analysis with local computing resources - is increasingly unsustainable. Not only are transfers slow and cost prohibitive, but this approach also leads to redundant and siloed compute infrastructure that makes it difficult to ensure security and compliance of protected data. The NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL; https://anvilproject.org) inverts this model, providing a unified cloud computing environment for data storage, management, and analysis. AnVIL eliminates the need for data movement, allows for active threat detection and monitoring, and provides scalable, shared computing resources that can be acquired by researchers as needed. This presents many new opportunities for collaboration and data sharing that will ultimately lead to scientific discoveries at scales not previously possible.

bioinformatics↗

bioRxiv2019

Exploring Integrative Analysis using the BioMedical Evidence Graph

The analysis of cancer biology data involves extremely heterogeneous datasets including information from RNA sequencing, genome-wide copy number, DNA methylation data reporting on epigenomic regulation, somatic mutations from whole-exome or whole-genome analyses, pathology estimates from imaging sections or subtyping, drug response or other treatment outcomes, and various other clinical and phenotypic measurements. Bringing these different resources into a common framework, with a data model that allows for complex relationships as well as dense vectors of features, will unlock integrative analysis. We introduce a graph database and query engine for discovery and analysis of cancer biology, called the BioMedical Evidence Graph (BMEG). The BMEG is unique from other biological data graphs in that sample level molecular information is connected to reference knowledge bases. It combines gene expression and mutation data, with drug response experiments, pathway information databases and literature derived associations. The construction of the BMEG has resulted in a graph containing over 36M vertices and 29M edges. The BMEG system provides a graph query based API to enable analysis, with client code available for Python, Javascript and R, and a server online at bmeg.io. Using this system we have developed several forms of integrated analysis to demonstrate the utility of the system. The BMEG is an evolving resource dedicated to enabling integrative analysis. We have demonstrated queries on the system that illustrate mutation significance analysis, drug response machine learning, patient level knowledge base queries and pathway level analysis. We have compared the resulting graph to other available integrated graph systems, and demonstrated that it is unique in the scale of the graph and the type of data it makes available.\n\nHighlightsO_LIData resource connected extremely diverse set of cancer data sets\nC_LIO_LIGraph query engine that can be easily deployed and used on new datasets\nC_LIO_LIEasily installed python client\nC_LIO_LIServer online at bmeg.io\nC_LI\n\nSummaryThe analysis of cancer biology data involves extremely heterogeneous datasets including information. Bringing these different resources into a common framework, with a data model that allows for complex relationships as well as dense vectors of features, will unlock integrative analysis. We introduce a graph database and query engine for discovery and analysis of cancer biology, called the BioMedical Evidence Graph (BMEG). The construction of the BMEG has resulted in a graph containing over 36M vertices and 29M edges. The BMEG system provides a graph query based API to enable analysis, with client code available for Python, Javascript and R, and a server online at bmeg.io. Using this system we have developed several forms of integrated analysis to demonstrate the utility of the system.

cancer biology↗

bioRxiv2018

neoepiscope Improves Neoepitope Prediction with Multi-variant Phasing

The vast majority of tools for neoepitope prediction from DNA sequencing of complementary tumor and normal patient samples do not consider germline context or the potential for co-occurrence of two or more somatic variants on the same mRNA transcript. Without consideration of these phenomena, existing approaches are likely to produce both false positive and false negative results, resulting in an inaccurate and incomplete picture of the cancer neoepitope landscape. We developed neoepiscope chiefly to address this issue for single nucleotide variants (SNVs) and insertions/deletions (indels), and herein illustrate how germline and somatic variant phasing affects neoepitope prediction across multiple datasets. We estimate that up to [~]5% of neoepitopes arising from SNVs and indels may require variant phasing for their accurate assessment. neoepiscope is performant, flexible, and supports several major histocompatibility complex binding affinity prediction tools. We have released neoepiscope as open-source software (MIT license, https://github.com/pdxgx/neoepiscope) for broad use.\n\nKEY POINTSO_LIGermline context and somatic variant phasing are important for neoepitope prediction\nC_LIO_LIMany popular neoepitope prediction tools have issues of performance and reproducibility\nC_LIO_LIWe describe and provide performant software for accurate neoepitope prediction from DNA-seq data\nC_LI

bioinformatics↗

bioRxiv2018

Creating Standards for Evaluating Tumour Subclonal Reconstruction

Tumours evolve through time and space. Computational techniques have been developed to infer their evolutionary dynamics from DNA sequencing data. A growing number of studies have used these approaches to link molecular cancer evolution to clinical progression and response to therapy. There has not yet been a systematic evaluation of methods for reconstructing tumour subclonality, in part due to the underlying mathematical and biological complexity and to difficulties in creating gold-standards. To fill this gap, we systematically elucidated the key algorithmic problems in subclonal reconstruction and developed mathematically valid quantitative metrics for evaluating them. We then created approaches to simulate realistic tumour genomes, harbouring all known mutation types and processes both clonally and subclonally. We then simulated 580 tumour genomes for reconstruction, varying tumour read-depth and benchmarking somatic variant detection and subclonal reconstruction strategies. The inference of tumour phylogenies is rapidly becoming standard practice in cancer genome analysis; this study creates a baseline for its evaluation.

bioinformatics↗

bioRxiv2018

Valection: Design Optimization for Validation and Verification Studies

BackgroundPlatform-specific error profiles necessitate confirmatory studies where predictions made on data generated using one technology are additionally verified by processing the same samples on an orthogonal technology. In disciplines that rely heavily on high-throughput data generation, such as genomics, reducing the impact of false positive and false negative rates in results is a top priority. However, verifying all predictions can be costly and redundant, and testing a subset of findings is often used to estimate the true error profile. To determine how to create subsets of predictions for validation that maximize inference of global error profiles, we developed Valection, a software program that implements multiple strategies for the selection of verification candidates.\n\nResultsTo evaluate these selection strategies, we obtained 261 sets of somatic mutation calls from a single-nucleotide variant caller benchmarking challenge where 21 teams competed on whole-genome sequencing datasets of three computationally-simulated tumours. By using synthetic data, we had complete ground truth of the tumours mutations and, therefore, we were able to accurately determine how estimates from the selected subset of verification candidates compared to the complete prediction set. We found that selection strategy performance depends on several verification study characteristics. In particular the verification budget of the experiment (i.e. how many candidates can be selected) is shown to influence estimates.\n\nConclusionsThe Valection framework is flexible, allowing for the implementation of additional selection algorithms in the future. Its applicability extends to any discipline that relies on experimental verification and will benefit from the optimization of verification candidate selection.

bioinformatics↗

bioRxiv2017

Combining accurate tumour genome simulation with crowd sourcing to benchmark somatic structural variant detection

BackgroundThe phenotypes of cancer cells are driven in part by somatic structural variants. Structural variants can initiate tumors, enhance their aggressiveness and provide unique therapeutic opportunities. Whole-genome sequencing of tumors can allow exhaustive identification of the specific structural variants present in an individual cancer, facilitating both clinical diagnostics and the discovery of novel mutagenic mechanisms. A plethora of somatic structural variant detection algorithms have been created to enable these discoveries, however there are no systematic benchmarks of them. Rigorous performance evaluation of somatic structural variant detection methods has been challenged by the lack of gold-standards, extensive resource requirements and difficulties arising from the need to share personal genomic information.\n\nResultsTo facilitate structural variant detection algorithm evaluations, we create a robust simulation framework for somatic structural variants by extending the BAMSurgeon algorithm. We then organize and enable a crowd-sourced benchmarking within the ICGC-TCGA DREAM Somatic Mutation Calling Challenge (SMC-DNA). We report here the results of structural variant benchmarking on three different tumors, comprising 204 submissions from 15 teams. In addition to ranking methods, we identify characteristic error-profiles of individual algorithms and general trends across them. Surprisingly, we find that ensembles of analysis pipelines do not always outperform the best individual method, indicating a need for new ways to aggregate somatic structural variant detection approaches.\n\nConclusionsThe synthetic tumors and somatic structural variant detection leaderboards remain available as a community benchmarking resource, and BAMSurgeon is available at https://github.com/adamewing/bamsurgeon.

bioinformatics↗

bioRxiv2017

Germline Contamination and Leakage in Whole Genome Somatic Single Nucleotide Variant Detection

BackgroundThe clinical sequencing of cancer genomes to personalize therapy is becoming routine across the world. However, concerns over patient re-identification from these data lead to questions about how tightly access should be controlled. It is not thought to be possible to re-identify patients from somatic variant data. However, somatic variant detection pipelines can mistakenly identify germline variants as somatic ones, a process called \"germline leakage\". The rate of germline leakage across different somatic variant detection pipelines is not well-understood, and it is uncertain whether or not somatic variant calls should be considered re-identifiable. To fill this gap, we quantified germline leakage across 259 sets of whole-genome somatic single nucleotide variant (SNVs) predictions made by 21 teams as part of the ICGC-TCGA DREAM Somatic Mutation Calling Challenge.\n\nResultsThe median somatic SNV prediction set contained 4,325 somatic SNVs and leaked one germline polymorphism. The level of germline leakage was inversely correlated with somatic SNV prediction accuracy and positively correlated with the amount of infiltrating normal cells. The specific germline variants leaked differed by tumour and algorithm. To aid in quantitation and correction of leakage, we created a tool, called GermlineFilter, for use in public-facing somatic SNV databases.\n\nConclusionsThe potential for patient re-identification from leaked germline variants in somatic SNV predictions has led to divergent open data access policies, based on different assessments of the risks. Indeed, a single, well-publicized re-identification event could reshape public perceptions of the values of genomic data sharing. We find that modern somatic SNV prediction pipelines have low germline-leakage rates, which can be further reduced, especially for cloud-sharing, using pre-filtering software.

genomics↗

bioRxiv2017

Population-level distribution and putative immunogenicity of cancer neoepitopes

BackgroundTumor neoantigens are a driver of cancer immunotherapy response; however, current neoantigen prediction tools produce many candidates that require further prioritization for research/clinical applications. Additional filtration criteria and population-level understanding may help to produce refined lists of putative neoantigens. Herein, we show neoepitope immunogenicity is likely related to measures of peptide novelty and report population-level behavior of these and other metrics.\n\nMethodsWe propose four peptide novelty metrics to refine predicted neoantigenicity: tumor vs. paired normal peptide binding affinity difference, tumor vs. paired normal peptide sequence similarity, tumor vs. closest human peptide sequence similarity, and tumor vs. closest microbial peptide sequence similarity. We apply these metrics to tumor neoepitopes predicted from somatic missense mutations in The Cancer Genome Atlas (TCGA) and a cohort of melanoma patients, as well as to a group of peptides with neoepitope-specific immune response data using an extension of pVAC-Seq [1].\n\nResultsWe show neoepitope burden varies across TCGA disease sites and HLA alleles, with surprisingly low repetition of neoepitope sequences across patients or neoepitope preferences among sets of HLA alleles. Only 20.3% of predicted neoepitopes across TCGA patients displayed novel binding change based on our binding affinity difference criteria. Similarity of amino acid sequence was typically high between paired tumor-normal epitopes, but in 24.6% of cases, neoepitopes were more similar to other human peptides, or even to bacterial (56.8% of cases) or viral peptides (15.5% of cases), than their paired normal counterparts. Applied to peptides with neoepitope-specific immune response, a linear model incorporating neoepitope binding affinity, protein sequence similarity between neoepitopes and their closest viral peptides, and paired binding affinity difference was able to predict immunogenicity with an AUROC of 0.66.\n\nConclusionsOur proposed neoepitope prioritization criteria emphasize neoepitope novelty and refine patient neoepitope predictions for focus on biologically meaningful candidate neoantigens. We have demonstrated that neoepitopes should be considered not only with respect to their paired normal epitope, but with respect to the entire human proteome, as well as bacterial and viral peptides, with potential implications for neoepitope immunogenicity and personalized vaccines for cancer treatment. We conclude that putative neoantigens are highly variable across individuals as a function of both cancer genetics and personalized HLA repertoire, while the overall behavior of filtration criteria reflects predictable patterns.

cancer biology↗

bioRxiv2017

Large-Scale Uniform Analysis of Cancer Whole Genomes in Multiple Computing Environments

The International Cancer Genome Consortium (ICGC)s Pan-Cancer Analysis of Whole Genomes (PCAWG) project aimed to categorize somatic and germline variations in both coding and non-coding regions in over 2,800 cancer patients. To provide this dataset to the research working groups for downstream analysis, the PCAWG Technical Working Group marshalled ~800TB of sequencing data from distributed geographical locations; developed portable software for uniform alignment, variant calling, artifact filtering and variant merging; performed the analysis in a geographically and technologically disparate collection of compute environments; and disseminated high-quality validated consensus variants to the working groups. The PCAWG dataset has been mirrored to multiple repositories and can be located using the ICGC Data Portal. The PCAWG workflows are also available as Docker images through Dockstore enabling researchers to replicate our analysis on their own data.

genomics↗